RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1412-1421

  Anton, Peter A ^a   Cranston, Ross D ^b   Kashuba, Angela ^c   Hendrix, Craig W ^d   Bumpus, Namandjé N ^d   Richardson Harman, Nicola ^e   Elliott, Julie ^a   Janocko, Laura ^f   Khanukhova, Elena ^a   Dennis, Robert ^a   Cumberland, William G ^g   Ju, Chuan ^g   Carballo Diéguez, Alex ^h   Mauck, Christine ⁱ   McGowan, Ian ^b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University of North Carolina   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALPHA STATCONSULT LLC   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYETHYLCELLULOSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; TENOFOVIR; TENOFOVIR DISOPROXIL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANUS FISSURE; AREA UNDER THE CURVE; ARTICLE; BLOATING; CLINICAL ARTICLE; COLON BIOPSY; COLON POLYP; CONSTIPATION; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG SAFETY; DRUG TISSUE LEVEL; EX VIVO STUDY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GEL; HEMORRHOID; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IN VIVO STUDY; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA RED SPOT; MULTICENTER STUDY; NAUSEA; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; RECTUM PAIN; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TENESMUS; UNITED STATES; VIRUS INFECTIVITY; VOMITING;

ADENINE; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; AGED; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PATIENT SATISFACTION; RECTUM; TREATMENT OUTCOME; UNITED STATES; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84868474359     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0262     Document Type: Article

References (41)

1. Prejean J, Song R, Hernandez A, et al.: Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011;6:e17502.
2. Jansen IA, Geskus RB, Davidovich U, et al.: Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: A 25-year prospective cohort study. AIDS 2011; 25:493-501.
3. Mosher WD, Chandra A, and Jones J: Sexual behavior and selected health measures: Men and women 15-44 years of age, United States, 2002. Adv Data 2005;362:1-55.
4. Misegades L, Page-Shafer K, Halperin D, and McFarland W: Anal intercourse among young low-income women in California: An overlooked risk factor for HIV? AIDS 2001; 15:534-535.
5. Gorbach PM, Manhart LE, Hess KL, et al.: Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis 2009;36:193-198.
6. Karim SS and Ramjee G: Anal sex and HIV transmission in women. Am J Public Health 1998;88:1265-1266.
7. Lane T, Pettifor A, Pascoe S, Fiamma A, and Rees H: Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS 2006;20:123-125.
8. Kalichman SC, Simbayi LC, Cain D, and Jooste S: Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 2009; 85:411-415.
9. Centers for Disease Control and Prevention (CDC): HIV transmission risk. Available at http://www.cdc.gov/hiv/law/transmission.htm.
10. Anton P and Herold BC: HIV transmission: Time for trans-lational studies to bridge the gap. Sci Transl Med 2011;3:77ps11.
11. McGowan I: Rectal microbicides: Can we make them and will people use them? AIDS Behav 2011;15(Suppl 1):S66-S71.
12. Anton PA: Future prospects and perspectives on micro-bicides. Curr HIV Res 2012;10:113-115.
13. U.S. Food and Drug Administration: FDA approval of Tru-vada for a PrEP indication: Label information. Available at http://www accessdata fda gov/scripts/cder/drugsatfda/index cfm?fuseaction =Search Label- ApprovalHistoryapphist 2012.
14. Abdool KQ, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral micro-bicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
15. Grant RM, Lama JR, Anderson PL, et al.: Preexposure che-moprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
16. Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
17. Karim SS, Kashuba AD, Werner L, and Karim QA: Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 2011;378:279-281.
18. Rohan LC, Moncla BJ, Kunjara N Ayudhya RP, et al.: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010;5:e9310.
19. Mayer KH, Maslankowski LA, Gai F, et al.: Safety and tol-erability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006;20:543-551.
20. Fuchs EJ, Lee LA, Torbenson MS, et al.: Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: Potential implication for HIV transmission. J Infect Dis 2007; 195:703-710.
21. Dezzutti CS, Rohan LC, Wang L, et al.: Reformulated teno-fovir gel for use as a dual compartment microbicide. J An-timicrob Chemother 2012;67:2139-2142.
22. Anton PA, Saunders T, Elliott J, et al.: First phase 1 doubleblind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 2011;6:e23243.
23. Schwartz JL, Ballagh SA, Kwok C, et al.: Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007;75:136-141.
24. CONRAD: Investigator's Brochure: Universal placebo gel. UC-781. Version 3.0. 2006. Arlington, VA, CONRAD, 2006.
25. Gaya DR, Lyon TD, Duncan A, et al.: Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005;98:435-441.
26. Patton DL, Cosgrove Sweeney YT, Rabe LK, and Hillier SL: Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis 2002;29:581-587.
27. McGowan I, Elliott J, Cortina G, et al.: Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007;46:417-425.
28. King T, Bushman L, Kiser J, et al.: Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci 2006;843:147-156.
29. Keller MJ, Madan RP, Torres NM, et al.: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity after application of 1% te-nofovir gel. PLoS One 2011;6:e16475.
30. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Bioanalytical METHOD VALIDATION. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001.
31. Fletcher PS, Elliott J, Grivel JC, et al.: Ex vivo culture of human colorectal tissue for the evaluation of candidate mi-crobicides. AIDS 2006;20:1237-1245.
32. Anton PA, Elliott J, Poles MA, et al.: Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000;14:1761-1765.
33. Schwartz JL, Kovalevsky G, Lai JJ, et al.: A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis 2008;35:414-419.
34. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, and Callahan MM: Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 2009;20:384-386.
35. Melchjorsen J, Risor MW, Sogaard OS, et al.: Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011;57:265-275.
36. Gumbi PP, Nkwanyana NN, Bere A, et al.: Impact of mu-cosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T cell responses in the female genital tract during chronic HIV infection. J Virol 2008; 82:8529-8536.
37. McGowan I, Elliott J, Fuerst M, et al.: Increased HIV-1 mu-cosal replication is associated with generalized mucosal cy-tokine activation. J Acquir Immune Defic Syndr 2004;37:1228-1236.
38. Zidek Z, Frankova D, and Holy A: Activation by 9-(R)-[2- (phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1a) and cytokine (tumor necrosis factor a, interleukin-10 [IL-10], IL-1b) production. Antimicrob Agents Chemother 2001;45:3381-3386.
39. th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, March 2012 [Paper #34LB].
40. Hendrix C, Minnis A, Guddera V, et al.: MTN-001: A phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations (#35LB). Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
41. Richardson-Harman N, Mauck C, McGowan I, Anton P: Dose response relationship between tissue concentrations of UC781 and explant infectibility with HIV-1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses 2012; [Epub ahead of print]; DOI:10.1089/aid.2012.0073.